Eli Lilly (LLY) Return on Equity (2009 - 2026)

Eli Lilly has reported Return on Equity for 17 years, with the latest figure at 0.01% in Q1 2026.

• For the quarter ending Q1 2026, Return on Equity rose 12.0% year-over-year to 0.01%; the trailing twelve-month figure through Mar 2026 stood at 0.01% (up 12.0% YoY), and the FY2025 full-year result was 0.02%, up 9.0% from the prior year.
• Return on Equity for Q1 2026 stood at 0.01%, up from 0.01% in the prior quarter.
• The five-year high for Return on Equity was 0.02% in Q3 2025, with the low at 0.13% in Q4 2024.
• Historically, Return on Equity has averaged 0.04% across 5 years, with a median of 0.03% in 2022.
• Annual changes were most pronounced in 2024 — Return on Equity decreased 10 bps — and 2025, when it rose 14 bps.
• Eli Lilly's Return on Equity stood at 0.03% in 2022, then declined by 15 bps to 0.03% in 2023, then slumped by 277 bps to 0.13% in 2024, then soared by 106 bps to 0.01% in 2025, then grew by 7 bps to 0.01% in 2026.
• The last three Return on Equity figures came in at 0.01% (Q1 2026), 0.01% (Q4 2025), and 0.02% (Q3 2025), per Business Quant data.